Ironwood Pharmaceuticals | IRWD - Sales Revenues


Ironwood Pharmaceuticals reported $106.51M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
Ardelyx USD 94.47M 30.74M Mar/2026
Astellas Pharma JPY 537.93B 33.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Charles River Laboratories USD 995.8M 1.6M Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
Moderna USD 389M 289M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
Pacira USD 177M 19.87M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024